Advertisement

Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S.

Published:December 17, 2020DOI:https://doi.org/10.1016/j.amepre.2020.09.005

      Introduction

      This study explores how human papillomavirus vaccination initiation and completion among men and women aged 18–34 years varies by geographic region.

      Methods

      Data from the 2015–2017 Behavioral Risk Factor Surveillance System were analyzed. Geographic regions for the selected states were defined as South, Northeast, and Midwest/West. Human papillomavirus vaccination initiation was defined as receipt of ≥1 dose, and completion was defined as receipt of ≥3 doses. Weighted, multivariable logistic regression models estimated the association between geographic region and vaccine uptake, adjusting for sociodemographic, health, and healthcare factors. Analyses were performed in November 2019.

      Results

      A total of 18,078 adults were included in the study, 80% of whom resided in the South. The overall vaccination initiation rate was 23.4%, and the completion rate was 11.0%. Initiation was higher among those who resided in the Northeast (38.6%), followed by Midwest/West (23.8%), and lowest for those in the South (21.8%) (p<0.0001). Completion rates followed the same trend as initiation. In the adjusted models, compared with the adults residing in the Northeast, those living in the South were less likely to initiate (AOR=0.47, 95% CI=0.40, 0.55) and complete (AOR=0.56, 95% CI=0.46, 0.68) human papillomavirus vaccination.

      Conclusions

      Human papillomavirus vaccine uptake was low for all regions, but vaccine uptake was significantly lower in the South region. This demonstrates the need to identify barriers specifically associated with the Southern population, which may include differing levels of education and insurance. Such work is especially pertinent because many Southern states face increased risk of human papillomavirus–associated cancers such as cervix and oral cavity and pharynx cancers.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Gillison ML
        • Chaturvedi AK
        • Lowy DR
        HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
        Cancer. 2008; 113: 3036-3046https://doi.org/10.1002/cncr.23764
        • Adjei Boakye E
        • Buchanan P
        • Hinyard L
        • Osazuwa-Peters N
        • Schootman M
        • Piccirillo JF
        Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma.
        JAMA Otolaryngol Head Neck Surg. 2018; 144: 727-737https://doi.org/10.1001/jamaoto.2018.0993
        • Suk R
        • Mahale P
        • Sonawane K
        • et al.
        Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers.
        JAMA Netw Open. 2018; 1e181999https://doi.org/10.1001/jamanetworkopen.2018.1999
        • Wang M
        • Sharma A
        • Osazuwa-Peters N
        • et al.
        Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers.
        Cancer Epidemiol. 2020; 64101649https://doi.org/10.1016/j.canep.2019.101649
        • Meites E
        • Szilagyi PG
        • Chesson HW
        • Unger ER
        • Romero JR
        • Markowitz LE
        Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 698-702https://doi.org/10.15585/mmwr.mm6832a3
        • Petrosky EY
        • Liu G
        • Hariri S
        • Markowitz LE
        Human papillomavirus vaccination and age at first sexual activity, National Health and Nutrition Examination Survey.
        Clin Pediatr (Phila). 2017; 56: 363-370https://doi.org/10.1177/0009922816660541
        • Walker TY
        • Elam-Evans LD
        • Yankey D
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2017 [published correction appears in MMWR Morb Mortal Wkly Rep. 2018;67(41):1164].
        MMWR Morb Mortal Wkly Rep. 2018; 67: 909-917https://doi.org/10.15585/mmwr.mm6733a1
        • Adjei Boakye E
        • Lew D
        • Muthukrishnan M
        • et al.
        Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States.
        Hum Vaccin Immunother. 2018; 14: 2016-2024https://doi.org/10.1080/21645515.2018.1467203
        • Rahman M
        • Laz TH
        • Berenson AB
        Geographic variation in human papillomavirus vaccination uptake among young adult women in the United States during 2008-2010.
        Vaccine. 2013; 31: 5495-5499https://doi.org/10.1016/j.vaccine.2013.09.022
        • Rahman M
        • Islam M
        • Berenson AB
        Differences in HPV immunization levels among young adults in various regions of the United States.
        J Community Health. 2015; 40: 404-408https://doi.org/10.1007/s10900-015-9995-2
        • Hirth JM
        • Rahman M
        • Smith JS
        • Berenson AB
        Regional variations in HPV vaccination among 9-17 year old adolescent females from the BRFSS, 2008-2010.
        Hum Vaccin Immunother. 2014; 10: 3475-3483https://doi.org/10.4161/21645515.2014.980202
        • Laz TH
        • Rahman M
        • Berenson AB
        An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010.
        Vaccine. 2012; 30: 3534-3540https://doi.org/10.1016/j.vaccine.2012.03.067
        • Wei F
        • Moore PC
        • Green AL
        Geographic variability in human papillomavirus vaccination among U.S. young women.
        Am J Prev Med. 2013; 44: 154-157https://doi.org/10.1016/j.amepre.2012.09.061
        • Wong CA
        • Berkowitz Z
        • Dorell CG
        • Anhang Price R
        • Lee J
        • Saraiya M
        Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008.
        Cancer. 2011; 117: 5612-5620https://doi.org/10.1002/cncr.26246
        • Liu G
        • Kong L
        • Du P
        HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the U.S.
        Papillomavirus Res. 2016; 2: 1-8https://doi.org/10.1016/j.pvr.2015.10.001
        • Chaturvedi AK
        • Engels EA
        • Pfeiffer RM
        • et al.
        Human papillomavirus and rising oropharyngeal cancer incidence in the United States.
        J Clin Oncol. 2011; 29: 4294-4301https://doi.org/10.1200/JCO.2011.36.4596
        • Chung CH
        • Gillison ML
        Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications.
        Clin Cancer Res. 2009; 15: 6758-6762https://doi.org/10.1158/1078-0432.CCR-09-0784
        • Viens LJ
        • Henley SJ
        • Watson M
        • et al.
        Human papillomavirus-associated cancers - United States, 2008-2012.
        MMWR Morb Mortal Wkly Rep. 2016; 65: 661-666https://doi.org/10.15585/mmwr.mm6526a1
        • Walker TY
        • Elam-Evans LD
        • Singleton JA
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 874-882https://doi.org/10.15585/mmwr.mm6633a2
        • Mokdad AH
        The Behavioral Risk Factors Surveillance System: past, present, and future.
        Annu Rev Public Health. 2009; 30: 43-54https://doi.org/10.1146/annurev.publhealth.031308.100226
        • Meites E
        • Kempe A
        • Markowitz LE
        Use of a 2-dose schedule for human papillomavirus vaccination–updated recommendations of the Advisory Committee on Immunization Practices.
        Am J Transplant. 2017; 17: 834-837https://doi.org/10.1111/ajt.14206
      1. Regional offices. Office of Intergovernmental and External Affairs. HHS. https://www.hhs.gov/about/agencies/iea/regional-offices/index.html. Updated April 15, 2014. Accessed January 31, 2020.

        • Adjei Boakye E
        • Zeng W
        • Governor S
        • et al.
        Differences in human papillomavirus (HPV) vaccine uptake by nativity status among men aged 18-34 years.
        Prev Med Rep. 2019; 16101010https://doi.org/10.1016/j.pmedr.2019.101010
        • Conrey R
        • Valencia V
        • Cioletti A
        • Williams-Brown MY
        Regional variation in human papillomavirus vaccination uptake and completion among adolescents 13-17 in the state of Texas.
        Vaccine. 2020; 38: 4119-4124https://doi.org/10.1016/j.vaccine.2020.03.059
        • Thompson EL
        • Wheldon CW
        • Rosen BL
        • Maness SB
        • Kasting ML
        • Massey PM
        Awareness and knowledge of HPV and HPV vaccination among adults ages 27-45 years.
        Vaccine. 2020; 38: 3143-3148https://doi.org/10.1016/j.vaccine.2020.01.053
        • Hirth JM
        • Kuo YF
        • Starkey JM
        • et al.
        Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014).
        Vaccine. 2019; 37: 4040-4046https://doi.org/10.1016/j.vaccine.2019.06.001
        • Zahnd WE
        • James AS
        • Jenkins WD
        • et al.
        Rural-urban differences in cancer incidence and trends in the United States.
        Cancer Epidemiol Biomarkers Prev. 2018; 27: 1265-1274https://doi.org/10.1158/1055-9965.EPI-17-0430
        • U.S. Cancer Statistics Working Group. U.S. Cancer statistics data visualizations tool, based on november 2018 submission data (1999-2016)
        HHS, Centers for Disease Control and Prevention and National Cancer Institute.
        2020 (Updated June 8, 2020. Accessed January 31, 2020)
        • Yoo W
        • Kim S
        • Huh WK
        • et al.
        Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States.
        PLoS One. 2017; 12e0172548https://doi.org/10.1371/journal.pone.0172548
        • Benard VB
        • Thomas CC
        • King J
        • et al.
        Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007-2012.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 1004-1009
        • Cubie HA
        • Seagar AL
        • Beattie GJ
        • Monaghan S
        • Williams ARW
        A longitudinal study of HPV detection and cervical pathology in HIV infected women.
        Sex Transm Infect. 2000; 76: 257-261https://doi.org/10.1136/sti.76.4.257
        • Beachler DC
        • Weber KM
        • Margolick JB
        • et al.
        Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults.
        Cancer Epidemiol Biomarkers Prev. 2012; 21: 122-133https://doi.org/10.1158/1055-9965.EPI-11-0734
        • HIV surveillance report
        Centers for Disease Control and Prevention.
        2020 (Updated June 30, 2020. Accessed January 31, 2020)
        • Stoecker C
        • Stewart AM
        • Lindley MC
        The cost of cost-sharing: the impact of Medicaid benefit design on influenza vaccination uptake.
        Vaccines (Basel). 2017; 5: 8https://doi.org/10.3390/vaccines5010008
        • Smith DB
        Racial and ethnic health disparities and the unfinished civil rights agenda.
        Health Aff (Millwood). 2005; 24: 317-324https://doi.org/10.1377/hlthaff.24.2.317
        • Vaccines for Children Program (VFC)
        Centers for Disease Control and Prevention.
        2016 (Updated February 18, 2016. Accessed June 14, 2017)
      2. The Merck patient assistance programs helps those in need. Merck Helps. https://www.merckhelps.com/Home.aspx. Accessed January 28, 2020.

        • Swiecki-Sikora AL
        • Henry KA
        • Kepka D
        HPV vaccination coverage among U.S. teens across the rural-urban continuum.
        J Rural Health. 2019; 35: 506-517https://doi.org/10.1111/jrh.12353
        • Mohammed KA
        • Subramaniam DS
        • Geneus CJ
        • et al.
        Rural-urban differences in human papillomavirus knowledge and awareness among U.S. adults.
        Prev Med. 2018; 109: 39-43https://doi.org/10.1016/j.ypmed.2018.01.016
        • Nguyen AB
        • Robinson J
        • O'Brien EK
        • Zhao X
        Racial and ethnic differences in tobacco information seeking and information sources: findings from the 2015 Health Information National Trends Survey.
        J Health Commun. 2017; 22: 743-752https://doi.org/10.1080/10810730.2017.1347216
      3. National Conference of State Legislatures. HPV vaccine: state legislation and regulation. Denver, CO: National Conference of State Legislatures.https://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx. Accessed January 31, 2020.

        • Mohammed KA
        • Geneus CJ
        • Osazuwa-Peters N
        • Adjei Boakye E
        • Tobo BB
        • Burroughs TE
        Disparities in provider recommendation of human papillomavirus vaccination for U.S. adolescents.
        J Adolesc Health. 2016; 59: 592-598https://doi.org/10.1016/j.jadohealth.2016.06.005
        • Senkomago V
        • Henley SJ
        • Thomas CC
        • Mix JM
        • Markowitz LE
        • Saraiya M
        Human papillomavirus–attributable cancers - United States, 2012–2016.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 724-728https://doi.org/10.15585/mmwr.mm6833a3